The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Continuous and Intermittent Glucose Monitoring in 2024
Dovč, K., Bode, B. W., & Battelino, T. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8802.kd · Cited by 2
Moving the Goalposts Closer: Using Intermediate End Points in Type 1 Diabetes Prevention Trials
Sydney, G. I., Wu, S., & Herold, K. C. (2025) · Diabetes Care · doi:10.2337/dci25-0041 · Cited by 1
Self-citationLuckett, A. M., McGrail, C., Murrall, K., Griffin, E. N., Beaumont, R. N., Hawkes, G., Hagopian, W., Rich, S. S., Weedon, M. N., Richardson, S. J., et al. (2025) · medRxiv · doi:10.1101/2025.08.13.25333386 · Cited by 1
Roma-Wilson, M. A., & Pozzilli, P. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109230 · Cited by 1
Thornton, T. D., Huang, M. L., Kodani, N., MA, R. C., & Jenkins, A. J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113189 · Cited by 1
A perspective on treating type 1 diabetes mellitus before insulin is needed
Tatović, D., Narendran, P., & Dayan, C. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00816-5 · Cited by 22
Antikörper bremst Typ-1-Diabetes-Entwicklung bei Menschen mit hohem Risiko
Kapellen, T. M. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1531-5
Fungal Infections in the Setting of Biological Therapies (in the Non-Transplant Host)
Lionakis, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21022-4
Les voies de recherche pour prévenir le diabète de type 1
Mallone, R. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.006
Pediatric Screenings: Helpful or Hinderance?
Papachrisanthou, M. M., & Fuller, K. M. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.07.014
Immunological Tolerance: Scanning a Barren Landscape for Signs of Sustained Growth
Petropoulos, H., Fairchild, P. J., & Davies, T. J. (2020) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2020.120
Health risk assessment and family history: Toward disease prevention
Martin, L. W., Prisco, L. C., Martínez-Prat, L., Mähler, M., & Sparks, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820239-5.00013-9
Lord, S. M., & Greenbaum, C. J. (2021) · Kompass Autoimmun · doi:10.1159/000516244
Self-citationAktuelle Entwicklungen in der Prävention des Typ-1-Diabetes
Hommel, A., & Reschke, F. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00759-3
Targeted pharmacological therapy restores β-cell function for diabetes remission
Sachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Böttcher, A., Sanchez-Garrido, M. A., Tarquis-Medina, M., Kleinert, M., Fischer, K. L., Jall, S., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.10.14
Mianowska, B. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.109489
Perinatal risk factors for type 1 diabetes in children and adolescents
Lindell, N. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-180918
Aktuelle Entwicklungen in der Prävention des Typ-1-Diabetes
Hommel, A., & Reschke, F. (2021) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-021-00152-x
Hope Injections: The Promises of Regenerative Medicine in Curing Type 1 Diabetes Mellitus.
Fanaropoulou, N. M. (2021) · PubMed
The etiology and pathogenesis of atherosclerosis.
Malmros, H. (1976) · PubMed
Concepts of Beta-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention
Charles, M. A., & Leslie, R. D. G. (2021) · doi:10.2337/figshare.15141837
Concepts of Beta-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention
Charles, M. A., & Leslie, R. D. G. (2021) · doi:10.2337/figshare.15141837.v1
Human Vaccines & Immunotherapeutics: news
(2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1642665
Achenbach, P. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1332-6287
Immune Intervention in Type 1 Diabetes
Nambam, B., Bratina, N., & Schatz, D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2513
Self-citationMössner, J., & Neubauer, A. (2019) · Der Internist · doi:10.1007/s00108-019-00680-4
Near infrared fluorescent sensors for selective glucose recognition
Sepasizangabadi, H. (2021) · doi:10.32469/10355/90169
Diabetes mellitus 2022 – Was ist neu?
Scherbaum, W. A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00924-2
Evolving Approaches to Type 1 Diabetes Management
Skyler, J. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_16
Self-citationKommentar zu Mehr Evidenz für Typ-1-Diabetes-Endotypen
Kamrath, C. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1732-9889
Alj., C., Inshaw, J. R. J., Flaxman, C. S., Leete, P., Wyatt, R. C., Russell, L. A., Palmer, M., Prasolov, D., Worthington, T., Hull, B., et al. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.10.7
Wiederherstellung der endogenen Insulinsekretion – Utopie oder Realität?
Lehmann, R., & Seufert, J. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00962-w
Früherkennung und Prävention des Typ-1-Diabetes
Hofelich, A., Marcus, B. A., & Achenbach, P. (2023) · Diabetes aktuell · doi:10.1055/a-2012-3790
IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.29
Felton, J. L., Griffin, K., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Evans‐Molina, C., DiMeglio, L. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.12.23288421
Self-citationTeplizumab: a new glimmer of hope for type 1 diabetic patients
Garg, P., Bhanwra, S., & Kumar, R. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20231135
Pieralice, S., D’Onofrio, L., & Buzzetti, R. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01264-z
Teplizumab: il primo farmaco “disease-modifying” approvato dall’FDA per il diabete mellito di tipo 1
Soldovieri, L., & Mezza, T. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01279-6
Aydemir, Ö., Bailey, J. A., Agardh, D., Lernmark, Å., Noble, J. A., Svärd, A. A., Blankenhorn, E. P., Parikh, H. M., Ziegler, A., Toppari, J., et al. (2026) · eLife · doi:10.7554/elife.89068.2
Self-citationTyp-1-Diabetes: Screening, Prävention und neue Therapien
Kick, K., Teichgräber, F. J., & Achenbach, P. (2023) · Diabetes aktuell · doi:10.1055/a-2093-9851
Mine, K., Nagafuchi, S., Akazawa, S., Abiru, N., Mori, H., Kurisaki, H., Yoshikai, Y., Takahashi, H., & Anzai, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.14.548984
Modeling Type 1 Diabetes progression from single-cell transcriptomic measurements in human isletsPreprint
Patil, A. R., Schug, J., Liu, C., Lahori, D., Descamps, H. C., Naji, A., Kaestner, K. H., Faryabi, R. B., & Vahedi, G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.19.549708
Munir, K. M., & Davis, S. N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2241354
Białek, J., Nitka, K., Więckowska-Deroń, M., Leszcz, M., ĆWIK-BŁOTNICKA, D., Borczyk, J., & Lewkowicz, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.44.01.018
Früherkennung und Prävention von Typ-1-Diabetes
Ziegler, A., & Hummel, S. (2023) · Pädiatrie · doi:10.1007/s15014-023-4923-x
Self-citationMoreira, R. M., Zarife, M. M. M., Fialho, M. E. D., Nicácio, T. F., Alonso, T. D., & Pereira, A. L. C. L. (2023) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/saude/mecanismos-imunologicos
Recurrence of Type 1 Diabetes Mellitus
Burke, G. W., Ciancio, G., Morsi, M., Figueiro, J., Chen, L., Sageshima, J., Vendrame, F., & Pugliese, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_56
Paradigmenwechsel in der Diabetologie
Zielinski, J. (2023) · Ernährung & Medizin · doi:10.1055/a-2147-2738
Inflammation and Diabetes Mellitus
Lim, S., Sarkar, S., & Ahima, R. S. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-39721-9_3 · Cited by 1
Ohuchi, S., Kajita, M., Tamaoka, A., & Ishii, K. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.2153
(2023) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-023-01860-1
Peng, W., Peng, X., Chen, M., Liu, X., Liu, X., Liu, L., & You, J. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4638793
Marrie, R. A., & Palladino, R. (2023) · Neurology · doi:10.1212/wnl.0000000000208070
Paradigmenwechsel beim Typ-1-Diabetes
Sonnet, M. (2023) · Pädiatrie · doi:10.1007/s15014-023-5023-7
Teplizumab: toma de posición de la Sociedad Argentina de Diabetes
Caracotche, L., Cerrone, G. E., Dios, A. D., Frechtel, G. D., Mazza, C., Perone, M. J., Pietropaolo, G., Trabucchi, A., Trifone, L., & Valdez, S. N. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v57i3.729
El desafío de prevenir y tratar una enfermedad con gran heterogeneidad
Tonietti, M. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v57i3.720
Heikkilä, T. E., Kaiser, E. K., Lin, J., Gill, D., Koskenniemi, J. J., & Karhunen, V. (2023) · medRxiv · doi:10.1101/2023.12.15.23300016
Teplizumab: an FDA- approved drug, marks milestone in treatment of type 1 diabetes
Mukhtar, S., & Haris, M. (2023) · International Journal of Scientific Reports · doi:10.18203/issn.2454-2156.intjscirep20233870
Akel, O., & Lernmark, Å. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch14
Immunotherapies for Type 1 Diabetes
Johannesen, J., & Pociot, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch76
Treatment and prevention of type 1 diabetes in the 21st century
Baidal, D. A., Sosenko, J. M., & Skyler, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00007-3
Self-citationPrevention of type 1 diabetes mellitus in children and adolescents
Bykov, Y. V. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202427011115
Az 1-es típusú diabetes mellitus immunterápiája
Kiss, K. A., Tóth, A., Schandl, L., Kiss, Z., Winkler, G., & Kis, J. T. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33000
Targeting immune system for the treatment of diabetes mellitus
Madan, S., & Nagpal, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00008-9
Immunomodulatory therapy in diabetes mellitus: A pharmacological approach
Eerike, M., & Konda, V. G. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00007-7
Tecnología aplicada a la diabetes
Cristoforetti, M. F. (2024) · doi:10.47196/0577
Die Diabetesinzidenz bei Kindern und Jugendlichen in Österreich steigt weiter!
Nagl, K. (2024) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-024-00223-9
Why consider screening for preclinical stages of type 1 diabetes in children?
Berka, B., Neuman, V., Průhová, Š., & Šumnı́k, Z. (2024) · Pediatrie pro praxi · doi:10.36290/ped.2024.014
Immunotherapy options for type 1 diabetes in children and adolescents
Průhová, Š., Berka, B., Neuman, V., & Šumnı́k, Z. (2024) · Pediatrie pro praxi · doi:10.36290/ped.2024.015
Cardona‐Hernandez, R., González, L. A. C., Atance, E. P., & Echevarría, I. R. (2024) · Anales de Pediatría · doi:10.1016/j.anpedi.2024.03.005
Teplizumab's breakthrough: a beacon of hope in the battle against type 1 diabetes mellitus
AHMAD, S. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04187-3
Diabetes in Children and Adolescents
Šumnı́k, Z., & Průhová, Š. (2023) · Endocrinology · doi:10.1007/978-3-030-18901-3_10-1
Stamceltherapieën bij type 1-diabetes: hoe staan we ervoor?
Noordzij, M. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1560-0
The Application and Prospects of Protein Therapy in the Treatment of T1DM
Ren, Z. (2024) · MedScien · doi:10.61173/5qhm2q41
Teplizumab rallenta la progressione del diabete tipo 1 di nuova insorgenza
Pieralice, S., & Buzzetti, R. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01475-y
Diabetes and Dyslipidemia Screening in Pediatric Practice.
Huston, J., Sudhakar, D., Malarvannan, P., Aradhyula, R., & Clark, A. L. (2024) · PubMed Central
Flash glucose monitoring in diabetes
Lameijer, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1021051970
Cardona‐Hernandez, R., Castaño, L. A., Atance, E. P., & Echevarría, I. R. (2024) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2024.03.051
Lai, X., Luo, J., Luo, Y., Zheng, Y., Yang, H. M., & Zou, F. (2024) · Research Square · doi:10.21203/rs.3.rs-4425280/v1
Renalase inhibition regulates β cell metabolism to defend against acute and chronic stressPreprint
MacDonald, T. L., Ryback, B. A., Pereira, J. A. D. S., Wei, S., Mendez, B., Cai, E. P., Ishikawa, Y., Weir, G. C., Bonner‐Weir, S., Kissler, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.11.598322
Type 1 diabetes: Prevention and screening in focus
Milicic, T. J., Jotić, A., Lukić, L., Macesic, M. V., Gajović, J. S., Stoiljkovic, M. M., Milovancevic, M. M., Rafailović, Đ., Božović, A., Radisavljević, N., et al. (2024) · Medicinska istrazivanja · doi:10.5937/medi57-49676
Updates in the Management of Type 1 Diabetes
Mallik, R., & Kar, P. S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0405
Autoimmune Form des Typ-1-Diabetes mellitus: Mit Kombinationstherapie einer Heilung näher kommen
Lenzen, S., & Jörns, A. (2024) · Deutsches Ärzteblatt · doi:10.3238/persdia.2024.06.28.02
Januszewski, A. S., Grzelka‐Woźniak, A., Flotyńska, J., Jenkins, A. J., Zozulińska‐Ziółkiewicz, D., & Uruska, A. A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108828
Therapeutic strategies for treating autoimmune disease
Smilek, D. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00057-6
Unnikrishnan, A., Lalvani, N., & Tiwari, S. (2024) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_1_24
Deniz, M. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006990 · Cited by 1
Comprensión y manejo de la diabetes mellitus: una revisión bibliográfica
Guevara, J. R. Z., Pineda, R., Morales, J. P., & Loor, T. A. S. (2024) · Revista Científica Multidisciplinaria SAPIENTIAE · doi:10.56124/sapientiae.v7i15.008 · Cited by 1
Advances in type 1 diabetes: Risk factors and prevention
Amutha, A., Ranjani, H., Anjana, R. M., Ranjit Unnikrishnan, I., & Mohan, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00038-3 · Cited by 1
Objetivos del tratamiento de la diabetes mellitus tipo 1
Cebada, A. B., da Silva, J. K. H., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.002 · Cited by 1
Etiopatogenia y situación epidemiológica de la diabetes mellitus tipo 1
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.001
Li, Y., Gunderson, R. C., Xu, Z., Ai, W., Shen, F., Ye, J., Xu, B., & Michie, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111350
General principles of endocrine genetics
Polychronakos, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00026-1
Wraith, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00019-9
Estado de la prevención de la diabetes mellitus tipo 1: promesas y realidades
Wägner, A. M., & García, M. H. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.10.002
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
The Laboratory Diagnosis of Diabetes Mellitus
Bailey, D. N., & Fitzgerald, R. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-67380-1_19
Sato, T., Tsujimoto, T., Kobayashi, M., & Kajio, H. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4648-24
Status of type 1 diabetes mellitus prevention: promises and realities
Wägner, A. M., & García, M. H. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.12.004
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
